Supplementary Material

**Supplementary Table 1.** Topical antihistamines available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | Emedastine 0.05% | QID |
| India | Emedastine 0.05%Levocabastine 0.05% | QIDQID |
| Indonesia | N/A |  |
| Malaysia | Antazoline 0.5% (+ xylometazoline 0.05%)Levocabastine 0.05% | QIDQID |
| Singapore | N/A |  |
| South Korea | N/A |  |
| Taiwan | Emedastine 0.05%  | QID |
| Thailand | Antazoline 0.05% (+ tetrahydrozoline 0.04%) | BID to QID |
| Vietnam | N/A |  |

BID: twice daily; N/A: not available; QID: four times daily.
This table is correct as of January 2021.

**Supplementary Table 2.** Mast cell stabilizers available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | DSCG 2%Lodoxamide 0.1% | BID to QIDBID to QID |
| India | DSCG 2% | BID to QID |
| Indonesia | DSCG 2%Pemirolast potassium 0.1% | TIDTID |
| Malaysia | DSCG 2%Lodoxamide 0.1% | BID to QIDBID to QID |
| Singapore | DSCG 2% | BID to QID |
| South Korea | DSCG 2%NAAGA 49 mg/mL | QIDBID to six times daily |
| Taiwan | DSCG 2% | BID to QID |
| Thailand | DSCG 2%Pemirolast potassium 0.1% | QIDBID |
| Vietnam | Lodoxamide 0.1% | TID |

BID: twice daily; DSCG: disodium cromoglycate; NAAGA: N-acetyl-aspartyl glutamic acid;
QID: four times daily; TID: three times daily.
This table is correct as of January 2021.

**Supplementary Table 3.** Dual-acting agents (antihistamines + mast cell stabilizers) available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | Alcaftadine 0.25% Azelastine 0.05%Epinastine 0.05%Ketotifen 0.025%Olopatadine 0.01–0.1% | QDBIDBIDBIDBID |
| India | Alcaftadine 0.25%Azelastine 0.05%Ketotifen 0.025%Olopatadine 0.1% | QDBIDBIDBID |
| Indonesia | Olopatadine 0.1% | BID |
| Malaysia | Azelastine 0.05%Epinastine 0.05%Ketotifen 0.025%Olopatadine 0.2% | QD to BIDBIDBIDQD to BID |
| Singapore | Alcaftadine 0.25%Ketotifen 0.025%Olopatadine 0.1% | QDBIDBID |
| South Korea | Alcaftadine 0.25%Azelastine 0.05%Bepotastine 1.5%Epinastine 0.05%Ketotifen 0.069%Olopatadine 0.1% | QDQD to BIDBIDBIDBID to QIDQD |
| Taiwan | Epinastine 0.05%Ketotifen 0.025%Olopatadine 0.1% | BIDBIDBID |
| Thailand | Alcaftadine 0.25%Epinastine 0.05%Ketotifen 0.025%Olopatadine 0.1% and 0.2% | QDBIDBIDQD to BID |
| Vietnam | Epinastine 0.05%Olopatadine 0.1% | BIDQD |

BID: twice daily; QD: once daily; QID: four times daily.
This table is correct as of January 2021.

**Supplementary Table 4.** Immunomodulators (calcineurin inhibitors) available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | CsA 0.05%, 0.1% and 0.5% | BID to QID |
| India | CsA 0.05% and 0.1%Tacrolimus 0.03% | BID to QIDQD |
| Indonesia | CsA 0.05% and 0.1% | TID |
| Malaysia | CsA 0.05% | BID to QID |
| Singapore | CsA 0.05%, 0.1% and 0.5%Tacrolimus 0.03% | BID to QIDQD |
| South Korea | CsA 0.02–0.1%Tacrolimus 0.03–0.1% | QD to QIDQD |
| Taiwan | CsA 0.05% and 0.1% | QD to QID |
| Thailand | CsA 0.05% and 0.1%Tacrolimus 0.03–0.1% | BID to QIDQD |
| Vietnam | CsA 0.05% | BID to QID |

\*Tacrolimus use in patients with VKC may be off-label. The concentrations presented for tacrolimus and CsA include commercial and hospital-compounded formulas. Availability and access to treatments may vary across clinics, hospitals, regions, and countries. Each treatment option should be considered in accordance with the level of evidence available at the time of the decision.
BID: twice daily, CsA: cyclosporine A; N/A: not available; QD: once daily; QID: four times daily; TID: three times daily.
This table is correct as of January 2021.

**Supplementary Table 5.** Topical corticosteroids available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | Dexamethasone 0.1%Fluorometholone 0.1%Loteprednol 0.5%Prednisolone acetate 1% | BID to QID (as required) |
| India | Betamethasone 0.1%Dexamethasone 0.1%Loteprednol 0.5%Fluorometholone 0.1%Prednisolone acetate 1% | BID to QID(as required) |
| Indonesia | Dexamethasone 0.1%Fluorometholone 0.1%Hydrocortisone 0.001–0.33%Prednisolone acetate 1% | TID to QID(as required) |
| Malaysia | Betamethasone 0.1%Dexamethasone 0.1%Loteprednol 0.5%Fluorometholone 0.1%Prednisolone acetate 1% | BID to QID(as required) |
| Singapore | Betamethasone 0.1%Dexamethasone 0.1%Fluorometholone 0.1%Loteprednol 0.5%Prednisolone acetate 1% | QD to hourly(as required) |
| South Korea | Dexamethasone 0.1–0.35%Fluorometholone 0.1%Loteprednol 0.5%Prednisolone acetate 1%Rimexolone 1% | QD to 12 times daily(as required) |
| Taiwan | Betamethasone 0.1%Dexamethasone 0.1%Fluorometholone 0.1%Loteprednol 0.5%Prednisolone acetate 1% | QD to hourly(as required) |
| Thailand | Dexamethasone 0.1%Fluorometholone 0.1%Loteprednol 0.2% and 0.5%Methylprednisolone (hospital formulas)Prednisolone acetate 1% | As required |
| Vietnam | Dexamethasone 0.1% (+ antibiotics; rarely used)Fluorometholone 0.1%Loteprednol 0.5% Prednisolone acetate 1% | As required |

BID: twice daily, QD: once daily; QID: four times daily; TID: three times daily.
This table is correct as of January 2021.

**Supplementary Table 6.** Systemic pharmacological treatment available for VKC by country (provided by the MOVIA Expert Working Group).

|  |  |  |
| --- | --- | --- |
| **Country/region** | **Drugs available** | **Dosing** |
| Hong Kong | Cetirizine 10 mgDesloratadine 5 mg Fexofenadine 120 mgLoratadine 10 mg | QD |
| India | Cetirizine 10 mgDesloratadine 5 mg Fexofenadine 120 mgLoratadine 10 mg | QD |
| Indonesia | Cetirizine 10 mg | BID to TID |
| Malaysia | Cetirizine 10 mgDesloratadine 5 mgFexofenadine 60 mgLevocetirizine 5 mgLoratadine 10 mgMontelukast 4 mg, 5 mg and 10 mg | QD |
| Singapore | Cetirizine 10 mgDesloratadine 5 mgFexofenadine 60 mgLoratadine 10 mgPheniramine 25–150 mgTerfenadine 60 mg and 120 mg | QD |
| South Korea | Cetirizine 10 mgDesloratadine 5 mgFexofenadine 120 mgLevocetirizine 5 mgMontelukast 10 mg | QD |
| Taiwan | Cetirizine 10 mgDesloratadine 5 mgFexofenadine 60 mgLevocetirizine 5 mgLoratadine 10 mgMontelukast 5–10 mg | QD |
| Thailand | Cetirizine 10 mgDesloratadine 5 mgFexofenadine 120 mgLoratadine 10 mg | QD |
| Vietnam | Fexofenadine 120 mg Loratadine 10 mg | QD |

BID: twice daily; QD: once daily; TID: three times daily.
This table is correct as of January 2021.